Promestriene

Summary

Promestriene (CHEMBL2105394) is a phase-3 clinical-stage small molecule (ATC G03CA09); indicated across 1 condition including hypospadias.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: G03CA09
• Indications: 1 condition
• Clinical trials: 6
• Chemistry: 328.5 Da · C22H32O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105394
Name	Promestriene
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9883915
ATC	G03CA09
Molecular formula	C22H32O2
Molecular weight	328.5
InChIKey	IUWKNLFTJBHTSD-AANPDWTMSA-N

SMILES: CCCOC1=CC2=C(C=C1)[C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4OC)C

IUPAC name: (8R,9S,13S,14S,17S)-17-methoxy-13-methyl-3-propoxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene

Also known as: Colpotrophine, Promestriene, Promestrieno, PROMESTRIENE, promestriene

Patent coverage: 3 distinct patent families (6 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5 (83%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypospadias	3	MONDO:0005345	EFO:0004209

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07153276	PHASE4	RECRUITING	TREATMENT OF VAGINAL DRYNESS IN SJÖGREN’S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE
NCT03032848	PHASE4	COMPLETED	Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients
NCT01370798	PHASE3	COMPLETED	Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications
NCT04232813	PHASE3	COMPLETED	Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream
NCT04081805	Not specified	ACTIVE_NOT_RECRUITING	LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)
NCT04717245	Not specified	COMPLETED	Comparative Study: Vaginal Promestriene Use, Fractional CO2 LASER and Radiofrequency in the Vaginal Atrophy Treatment

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).